SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors react to the company's recent listing transfer to the Nasdaq Global Select Market and ongoing focus on the commercial rollout of its fibromyalgia treatment, Tonmya. While the community is actively debating the stock's long-term potential and leadership, discussions are dominated by the tension between the product's prescription growth and concerns over share dilution and the company's cash runway.

Trump For President

TRUMP crypto is currently trending amidst intense community debate over its perceived status as a pump-and-dump scheme and frustration regarding the coin's steep decline from previous highs. Investors and critics alike are actively discussing its connection to broader political controversies and the waning sentiment surrounding Trump-affiliated tokens.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending as investors respond to renewed interest in edge AI hardware following industry-wide shifts, alongside anticipation for upcoming corporate presentations and performance benchmarks. Community discussion is sharply divided between bullish expectations regarding potential defense-sector integration and vocal skepticism from traders questioning the company's technical claims and historical transparency.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment remains volatile as investors digest escalating geopolitical tensions in the Middle East and concerns over surging energy prices. The community is actively debating the impact of these geopolitical developments on broad market indices, with widespread discussion around potential interest rate adjustments and hedging strategies in response to persistent economic uncertainty.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility and massive trading volumes as the escalating conflict in the Middle Eastspecifically surrounding the Strait of Hormuzdrives fears of a historic global supply shock. While the community remains sharply divided, traders are actively debating whether current price levels are sustainable given potential supply-side interventions and conflicting signals regarding future oil tanker safety.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is facing heightened volatility as investors grapple with a surge in oil prices and escalating geopolitical tensions in the Middle East. Community discussions are dominated by concerns over potential economic fallout, with traders debating whether to buy the dip or prepare for further downside as market sentiment turns increasingly cautious.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant volatility and heightened trading volume as investors debate the impact of potential tariff refunds and regional geopolitical tensions on its consumer-facing business model. While some in the community are using the price swings to accumulate shares, others are expressing frustration over the stock's sensitivity to macroeconomic headlines and the upcoming earnings outlook.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

Investors are gravitating toward VOO as a core holding to navigate current market volatility and geopolitical uncertainty, while community discourse remains focused on comparing the structural decay of leveraged ETFs against the long-term compounding benefits of S&P 500 index funds. Discussion is centered on the influence of institutional capital flows and the broader debate over passive versus active strategies during periods of heightened economic concern.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is currently facing significant downward pressure as traders aggressively accumulate short-dated puts, signaling institutional concern over near-term volatility and potential downside. While some investors remain optimistic about the company's dual-platform technology and government partnerships, the community is actively debating the stock's speculative nature and recent technical weakness, with many urging caution against dip-buying until clear signs of stabilization emerge.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently facing intense debate as investors weigh the impact of potential tokenomics changes and ongoing foundation management concerns against the promise of its underlying technology. While some community members are aggressively accumulating positions in anticipation of a potential long-term reversal, others remain highly skeptical due to the asset's sustained decline and ongoing market headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medical ETF (MEDX) Touches New 52-Week High

MEDX hits a new 52-week high, as strength in patented pharma fuels fresh momentum.

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

Equity

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 


MEDX
Medarex, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest MEDX News

MEDXMedarex, Inc.